Apart from their effects on the amelioration of insulin resistance and T2D, synthetic ligands of PPARγ, i.e., TZDs (thiazolidinediones), have emerged as a promising drug to reduce proteinuria and mitigate the progression of DN, irrespective of glycemic control [127,128,129]. The gene discussed is PPARG; the disease is liver dysplastic nodule.